PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg July 2, 2024 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Asia FX muted as dollar steadies ahead of rate cues; yen weakens further Back: All Posts Next:Australia gives internet firms 6 months to draft online child-safety rules